Scarica l'app Stockscreener
21.04
2.14%
-0.46
Dopo l'orario di chiusura:
21.19
0.15
+0.71%
Precedente Chiudi:
$21.50
Aprire:
$21.04
Volume 24 ore:
482.22K
Relative Volume:
2.00
Capitalizzazione di mercato:
$2.73B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-2.00%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$20.75
$21.77
Intervallo di 1 settimana:
$20.75
$23.62
Portata 52W:
$20.75
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Nome
Kailera Therapeutics Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare KLRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
21.04 | 2.79B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kailera Therapeutics Inc Borsa (KLRA) Ultime notizie
How AI is Transforming Health Literacy and Engagement - William Blair
RTW Bio NAV Rises 7.0% In April As Biotech IPO And M&A Activity Accelerates - DirectorsTalk Interviews
Evercore Initiates Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
TD Cowen Initiates Kailera Therapeutics(KLRA.US) With Buy Rating, Announces Target Price $57 - Moomoo
Kailera Therapeutics, Inc. (KLRA) Total Expenses (TTM) - Zacks Investment Research
What's Going On With Kailera Therapeutics Stock Wednesday?Kailera Therapeutics (NASDAQ:KLRA) - Benzinga
Kailera Therapeutics, Inc. (KLRA) Profit Margin (Quarterly) - Zacks Investment Research
Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions - ChartMill
Kailera Therapeutics, Inc. (KLRA) Dividend Yield (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Market Cap - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Revenue (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Book Value (Per Share) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Net Income (Quarterly) - Zacks Investment Research
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
Kailera's record IPO headlines strong April for biopharma financings - BioWorld News
A Quick Look at Today's Ratings for Kailera Therapeutics(KLRA.US), With a Forecast Between $30 to $48 - Moomoo
Kailera Therapeutics (KLRA) Stock Forecast and Price Target 2026 $KLRA - MarketBeat
Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge - BioSpace
JPMorgan Initiates Kailera Therapeutics at Overweight With $30 Price Target - marketscreener.com
Evercore ISI Kailera Therapeutics Initiates at Outperform - Moomoo
Investment bank Leerink Partners announces the initiation of research coverage on biopharmaceutical company Kailera Therapeutics. - Bitget
TD Cowen initiates Kailera stock with buy on weight loss drug potential - Investing.com Canada
Top Hyperliquid Strategies (PURR) Competitors 2026 - MarketBeat
William Blair initiates Kailera stock with Outperform rating By Investing.com - Investing.com Canada
JPMorgan initiates Kailera stock at Overweight on obesity pipeline By Investing.com - Investing.com Canada
This Southwest Gas Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Kailera Therapeutics, Inc. (KLRA) Revenue (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Dividend (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Free Cash Flow (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Total Long Term Debt (Quarterly) - Zacks Investment Research
Odyssey raises $304 million in upsized Nasdaq debut - The Pharma Letter
Kailera Therapeutics, Inc. (KLRA) Price To Free Cash Flow - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Gross Profit (TTM) - Zacks Investment Research
KLRA: Kailera Therapeutics, Inc.12 Month EPS - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Earnings Yield (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Return On Equity (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Revenue (Quarterly) Yoy Growth - Zacks Investment Research
KLRA : Kailera Therapeutics, Inc. Key Company Details - Zacks Investment Research
IPO Tracker 2026: Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq - BioSpace
Kailera Therapeutics, Inc. (KLRA) Debt Equity Ratio (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Cash From Operations (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Book Value - Zacks Investment Research
Biotech firm Odyssey hits nearly $900 million valuation as shares rise in Nasdaq debut - WNWN-FM
Kailera Therapeutics, Inc. Stock Data and SignalsKLRA - StockInvest.us
Kailera Therapeutics, Inc. (KLRA) Total Liabilities - Zacks Investment Research
Number of shareholders of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics, Inc. (KLRA) Cash From Financing (Quarterly) - Zacks Investment Research
Biotech firm Odyssey raises $279 million in upsized US IPO - 102.7 WBOW
Kailera Therapeutics, Inc. (KLRA) Price To Cash Flow - Zacks Investment Research
Kailera Therapeutics (KLRA) Stock Analysis Report | Financials & Insights - Benzinga
Kailera Therapeutics Inc Azioni (KLRA) Dati Finanziari
Non sono disponibili dati finanziari per Kailera Therapeutics Inc (KLRA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Kailera Therapeutics Inc Azioni (KLRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
| Koppel Adam | Director |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Bain Capital Life Sciences Inv | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Kaplan Andrew T. | Director |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):